## Distinguishing Graves' Disease from Toxic Multinodular Goiter ### Key Discriminating Feature **Key Point:** Exophthalmos and pretibial myxedema are pathognomonic for Graves' disease and are absent in toxic multinodular goiter. These extrathyroidal manifestations result from TSH receptor antibodies (TRAb) activating TSH receptors in orbital fibroblasts and skin fibroblasts. ### Comparison Table | Feature | Graves' Disease | Toxic Multinodular Goiter | | --- | --- | --- | | **Exophthalmos** | Present (20–40% of cases) | Absent | | **Pretibial myxedema** | Present (rare, <5%) | Absent | | **Pathophysiology** | Autoimmune (TRAb-mediated) | Autonomous nodular function | | **TSH receptor antibodies** | Positive | Negative | | **Thyroid appearance** | Diffuse, smooth enlargement | Multiple nodules | | **Remission rate** | 30–50% with antithyroid drugs | No remission; requires ablation | | **Age of onset** | Younger (20–40 years) | Older (>50 years) | ### Why Other Options Are Incorrect **High-Yield:** While elevated TPO antibodies and suppressed TSH occur in both conditions, they are not discriminators. TPO positivity is common in Graves' disease but can also occur in chronic thyroiditis. Suppressed TSH is a feature of any hyperthyroid state. **Clinical Pearl:** Diffuse thyroid enlargement is typical of Graves' disease, but toxic multinodular goiter may also present with a palpably enlarged thyroid if the nodules are large enough to cause overall gland expansion. ### Mechanism of Extrathyroidal Manifestations **Key Point:** TSH receptor antibodies in Graves' disease cross-react with TSH receptors expressed on: - Orbital fibroblasts and adipocytes → exophthalmos - Dermal fibroblasts → pretibial myxedema These manifestations are **unique to Graves' disease** and do not occur in other causes of hyperthyroidism, making them the single best discriminator. [cite:Harrison 21e Ch 405]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.